PIK3CA and colorectal carcinoma: Several clinical trials are ongoing to evaluate the efficacy of PI3K inhibitors in CRC patients with PIK3CA mutations to determine whether targeting the PI3K pathway can improve treatment outcomes in specific patient populations [336,337].